<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

Patient Monitoring Post-CAR T Therapy using Flow Cytometry and Functional Proteomic Analysis.

Posted on: March 18, 2021

Introduction of CAR-T Therapy

T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR) in CAR-T Cell therapy. The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. (Zhai et al. 2018). Chimeric antigen receptors (CARs) cells have recombinant receptor constructs expressed in T cells to target cells expressing specific antigens.

Read The Entire Blog Post »

CAR-NK Cell Therapy Flow Cytometry Assay

Posted on: March 04, 2021

What is the Primary Role of Natural killer (NK) cells?  

Natural killer (NK) cells are the predominant innate immune cells that mediate anti-tumor and anti-viral responses, and therefore possess good clinical utilization (Abel et al. 2018). Natural killer cells comprise 10–15% of peripheral blood lymphocytes and classically display a half-life of approximately 7–10 days in the circulation (Moretta et al. 2000).

Read The Entire Blog Post »

What is Vaccine Efficacy? - Vaccine Efficacy Explained

Posted on: February 18, 2021

All of us are now either looking forward to receiving our Covid-19 Vaccine, or have been fortunate enough to have recently been given our first or second dose. Upon departure from the vaccine clinic, you were most likely reminded to maintain social distancing and facemask wearing for the foreseeable future. But why do we still need to do these things even after we are vaccinated? Well, there are several reasons: firstly, it takes several days to weeks for the immune system to build a robust response to the  Vaccine, and during this time, the individual has limited or no protection from infection; secondly, the Vaccine works to a different degree for every one of us, and so our level of protection, and the duration of that protection is not well understood right now. To complicate things more, it is still unclear if vaccination prevents an individual from spreading the virus, even if they do not display any symptoms. With so many unknowns, it makes sense that we should continue to take these safety precautions for the foreseeable future.

Read The Entire Blog Post »

Covid-19 vaccines, the Latest Developments

Posted on: February 03, 2021

As we move into 2021, we are now hit with the stark reality that Covid-19 is still with us. To date, across the globe more than 2.03 million people have died from COVID-19 and confirmed infections now exceed 90 million. Sadly, the pandemic is still evolving, with new variants of the SARS-CoV-2 virus emerging from the UK, Brazil and South Africa. Effective therapeutic drugs for severe cases and effective vaccines for the healthy people are in urgent need within every country (Zhang et al 2020). In response to the pandemic the scientific community in general has portrayed the development of safe and effective vaccines against the SARS-CoV-2 virus as the perverbial “light at the end of the tunnel”.

Read The Entire Blog Post »

Future Solutions to Expand Access to CAR-Based Immunotherapies

Posted on: January 15, 2021

Chimeric Antigen Receptor (CAR) T-cell therapy has delivered major advancements in the treatment of lymphoid malignancies. However, the FDA approval of two of these therapies, tisagenlecleucel (Novartis) and axicabtagene ciloeucel (Kite Pharma) has highlighted the many barriers to broader access and adoption. These barriers range from high price-points and the unwillingness of insurance companies to cover these treatments, to manufacturing and Quality Control challenges, and the potential for toxicities in patients. We discuss here some of the future solutions to help bring this technology to mainstream medicine, and how flow cytometry is being utilized to help ensure the safety and efficacy of this magic bullet.  

Read The Entire Blog Post »